RCUS
insider transactionsArcus Biosciences, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 30d
-2.6K
0 buy · 2.6K sell
Net value · 30d
-$66.0K
$0 in · $66.0K out
Sentiment · 30d
Net selling
0% buying · 100% selling
Open-market trades · 30d
1
0 buy · 2.6K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Exercise·M
General Counsel
$87.7K
34.1K sh · $2.57
Own New
-
Exercise·M
General Counsel
$87.7K
34.1K sh · $2.57
Own +23%
-
Grant·A
Director
$0
16.9K sh
Own New
-
Grant·A
Director
$0
5.7K sh
Own +15%
-
Grant·A
Director
$0
16.9K sh
Own New
-
Grant·A
Director
$0
5.7K sh
Own +15%
-
Grant·A
Director
$0
16.9K sh
Own New
-
Grant·A
Director
$0
5.7K sh
Own +8%
-
Grant·A
Director
$0
16.9K sh
Own New
-
Grant·A
Director
$0
5.7K sh
Own +15%
-
Grant·A
Director
$0
16.9K sh
Own New
-
Grant·A
Director
$0
5.7K sh
Own +28%
-
Grant·A
Director
$0
16.9K sh
Own New
-
Grant·A
Director
$0
5.7K sh
Own +15%
-
Grant·A
Director
$0
16.9K sh
Own New
-
Grant·A
Director
$0
5.7K sh
Own +13%
-
Sell·S
Chief Accounting Officer · 10b5-1
$66.0K
2.6K sh · $25.77
Own -6%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 11, 2026 | Carolyn C. Tang | Exercise M | 34.1K | $87.7K |
| Jun 11, 2026 | Carolyn C. Tang | Exercise M | 34.1K | $87.7K |
| Jun 11, 2026 | Antoni Ribas | Grant A | 16.9K | $0 |
| Jun 11, 2026 | Antoni Ribas | Grant A | 5.7K | $0 |
| Jun 11, 2026 | Nicole Lambert | Grant A | 16.9K | $0 |
| Jun 11, 2026 | Nicole Lambert | Grant A | 5.7K | $0 |
| Jun 11, 2026 | David L. Lacey | Grant A | 16.9K | $0 |
| Jun 11, 2026 | David L. Lacey | Grant A | 5.7K | $0 |
| Jun 11, 2026 | Patrick Machado | Grant A | 16.9K | $0 |
| Jun 11, 2026 | Patrick Machado | Grant A | 5.7K | $0 |
| Jun 11, 2026 | Yasunori Kaneko | Grant A | 16.9K | $0 |
| Jun 11, 2026 | Yasunori Kaneko | Grant A | 5.7K | $0 |
| Jun 11, 2026 | Kathryn E Falberg | Grant A | 16.9K | $0 |
| Jun 11, 2026 | Kathryn E Falberg | Grant A | 5.7K | $0 |
| Jun 11, 2026 | Andrew J Perlman | Grant A | 16.9K | $0 |
| Jun 11, 2026 | Andrew J Perlman | Grant A | 5.7K | $0 |
| Jun 1, 2026 | Alexander Azoy 10b5-1 | Sell S | 2.6K | $66.0K |
About RCUS insider trading
This page tracks insider transactions for Arcus Biosciences, Inc. (RCUS) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.